Peptides to Preserve Muscle on GLP-1: What the Evidence Shows

About a quarter of the weight lost on a GLP-1 drug like semaglutide (Wegovy) or tirzepatide (Zepbound) is lean mass — a mix of skeletal muscle, water, and supporting tissue ^[3]. That number worries anyone who has worked hard to build strength, and the wellness industry has a ready answer: peptides. Sermorelin, ipamorelin, CJC-1295, BPC-157, and tesamorelin are all marketed, in various combinations, as tools to “preserve muscle” during GLP-1-driven weight loss. This article evaluates what the human evidence actually shows — and the honest answer is that none of these peptides has been tested in a human clinical trial for muscle preservation during GLP-1 therapy. The evidence-based levers are resistance training and adequate dietary protein, and that fact is not a footnote.

Why GLP-1s cause lean-mass loss in the first place

GLP-1 receptor agonists suppress appetite profoundly, which is how they work. SURMOUNT-1 (Jastreboff 2022 ^[1]) randomized 2,539 adults with obesity to tirzepatide or placebo for 72 weeks; the 15 mg arm lost a mean of −20.9% total body weight versus −3.1% on placebo. STEP-1 (Wilding 2021 ^[2]) showed semaglutide 2.4 mg produced −14.9% total body weight at 68 weeks. These are the largest intentional weight-loss effects ever documented in a medication trial.

Large, sustained weight loss — from any cause — draws on both fat stores and lean tissue. The pre-specified body composition sub-study of SURMOUNT-1 (Look 2025 ^[3]) added serial DXA scans to 160 participants and found that, on the tirzepatide 10 mg arm at 72 weeks, fat mass fell by −33.9% and lean mass fell by −10.9%, with lean mass representing roughly 25% of the total weight lost. Crucially, the placebo arm showed nearly the same fat-to-lean ratio — meaning the lean-mass fraction tracks the size of the deficit, not the specific drug. The same proportion appears across decades of diet-only weight-loss studies (Cava 2017 ^[7]). The biology is straightforward: when you eat substantially less than you burn, the body draws on both fat and muscle protein to cover the shortfall. GLP-1 drugs make it easy to sustain a very large deficit; that deficit is the proximate cause of lean-mass loss. For the full mechanism, see our companion article on the biology of muscle loss on a GLP-1.

The peptides people try — and what the human evidence shows

A growing number of compounding clinics and wellness prescribers add one or more of the following peptides to GLP-1 protocols, marketing them as muscle-sparing agents. Here is what the published human evidence actually says about each, specifically for skeletal muscle preservation.

Sermorelin

Sermorelin is a synthetic analogue of the first 29 amino acids of growth-hormone-releasing hormone (GHRH). Its only FDA approval was as Geref for pediatric growth-hormone deficiency — a brand that has since been discontinued. A PubMed search for sermorelin and weight loss, obesity, fat loss, or muscle preservation returns no human randomized trial. The weight-loss and body-composition claims extrapolate from indirect GH/IGF-1 data or from the broader GHRH-analogue literature. No published RCT has tested sermorelin against a placebo for muscle preservation in any population, let alone in GLP-1 therapy.

Ipamorelin

Ipamorelin is a selective growth-hormone secretagogue receptor (GHSR) agonist — a ghrelin mimetic. Its published human data consists of: a pharmacokinetic/pharmacodynamic modeling study in healthy volunteers showing it raises GH levels with fewer cortisol and prolactin side effects than earlier secretagogues (Gobburu 1999 ^[6]), and a clinical trial in post-bowel-resection patients where it reduced postoperative ileus. There is no published human RCT evaluating ipamorelin for lean-mass preservation during weight loss or during GLP-1 therapy. Ipamorelin is not FDA-approved for any indication.

CJC-1295

CJC-1295 is a long-acting GHRH analogue designed for weekly or bi-weekly dosing. The pivotal human study (Teichman 2006 ^[5]) enrolled 65 healthy adults aged 21–61 and demonstrated that single and multiple doses of CJC-1295 produced sustained, dose-dependent increases in GH (up to 10-fold) and IGF-1 (1.5–3-fold) lasting 6–8 days. The study measured GH and IGF-1 — not body composition, lean mass, or muscle performance. Raising GH and IGF-1 is a mechanism that could theoretically support muscle protein synthesis, but there is no published RCT in humans showing CJC-1295 preserves muscle mass during caloric restriction or GLP-1 therapy. CJC-1295 is not FDA-approved.

BPC-157

BPC-157 (body protective compound 157) is a synthetic peptide derived from a gastric protein. Its preclinical literature in rodents is extensive, spanning GI healing, tendon repair, and anti-inflammatory effects. The human evidence, however, consists of one published trial — a 1999 RCT in inflammatory bowel disease patients (not a body-composition study). There are no published human data on BPC-157 and skeletal muscle mass, lean mass preservation, or muscle outcomes during weight loss. BPC-157 is not FDA-approved and the FDA issued a warning in 2022 clarifying that compounded BPC-157 products are not legally marketed as drugs.

Tesamorelin

Tesamorelin (Egrifta SV / Egrifta WR) is the only peptide in this group that is actually FDA-approved — but its sole approved indication is the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The phase 3 pivotal trial (Falutz 2007 ^[4]) randomized 412 HIV-positive adults receiving antiretroviral therapy to tesamorelin or placebo for 26 weeks. Tesamorelin reduced trunk fat area by −18% versus +5% for placebo. The study measured visceral adipose tissue and metabolic markers — not skeletal muscle mass, and not in people taking a GLP-1 agonist. Lean mass was reported as roughly stable, but stability in an already-lean HIV lipodystrophy population receiving treatment for a fat redistribution syndrome is not the same as “muscle preservation during GLP-1-driven weight loss” in people with obesity. Tesamorelin is not approved for obesity, weight loss, or use alongside GLP-1 therapy.

Summary table: evidence by peptide

What is actually evidence-based: resistance training and protein

Two interventions have replicated human evidence for blunting lean-mass loss during caloric restriction, and both work in GLP-1 users.

Resistance training

Sardeli 2018 (Nutrients ^[8]) systematically reviewed and meta-analyzed six RCTs of resistance training during caloric restriction in obese older adults. Diet alone produced lean-mass loss averaging about 5% of baseline. Diet plus resistance training produced effectively no lean-mass loss. The training protocols used 2–3 sessions per week of compound movements (squat, press, row, deadlift pattern). The finding is mechanistically coherent: resistance exercise stimulates muscle protein synthesis through the mTOR pathway, directly counteracting the deficit-driven reduction in synthesis. See also the companion evidence review on GLP-1 muscle-loss prevention protocol for the practical implementation.

Adequate dietary protein

Cava 2017 (Advances in Nutrition ^[7]) reviewed the evidence for preserving healthy muscle during weight loss and concluded that protein intake is the primary dietary lever. The threshold dose is approximately 1.2–1.6 g of protein per kilogram of body weight per day (evidence reviewed in Cava 2017 ^[7]). GLP-1-driven appetite suppression frequently pushes intake below this range, which is why tracking protein — not total calories — is the priority for GLP-1 users concerned about lean mass. Animal-source proteins (whey, eggs, poultry, fish) provide the leucine density needed to maximally stimulate muscle protein synthesis per gram.

The evidence hierarchy is clear: resistance training + protein adequacy is the combination with replicated human RCT support. Peptides are an unvalidated add-on that costs money, involves injections, and carries regulatory and safety uncertainty — particularly for compounded preparations without FDA manufacturing oversight.

Should you discuss any of these peptides with your prescriber?

The honest framing: none of the peptides discussed here are FDA-approved for muscle preservation or for use alongside GLP-1 therapy. Tesamorelin is the one with real clinical-trial data, but it is approved only for HIV lipodystrophy and is typically not indicated for obesity or GLP-1 co-administration. If a clinic is offering you one of these peptides alongside your GLP-1, the appropriate questions are: “Is this FDA-approved for this purpose?” (answer: no, for all five), and “Is there a human RCT showing it preserves muscle during GLP-1 therapy?” (answer: no, for all five). The most important question — “Are you doing resistance training and eating enough protein?” — is the one most worth answering yes to. For a full index of peptides and what the human evidence says for each, see the peptide directory.